Disease Filter Sample

Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)

The purpose of this study is to learn more about eosinophilic granulomatosis with polyangiitis (EGPA) that returns (relapse) or has not responded to treatment, and if the investigational drug depemokimab can improve the disease. This study is being done to help determine if depemokimab is safe and how it works compared to mepolizumab. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA. Depemokimab is being compared to mepolizumab, which is approved by the FDA to treat EGPA. We will use your personal health information, information from the tests and procedures done for the study, and information about how the study drug affects you to help determine if depemokimab is safe and effective in treating EGPA.

Study Duration: Approximately 1 year

Disease(s): Granulomatosis with Polyangiitis (GPA)

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (LoDoNaVasc)

Vasculitis may cause pain, fatigue, problems with mood, difficulty sleeping, and difficulty with activities, resulting in a lower health-related quality of life for many patients. Naltrexone is a prescription drug approved for a different reason at a higher dose than the dose used in this study. However, “low-dose naltrexone” is widely used for a wide range of conditions associated with pain or fatigue. We hope to learn more about the impact of low-dose naltrexone on the symptoms caused by vasculitis.

Study Duration: 12 weeks

Disease(s): Eosinophilic Granulomatosis with Polyangiitis (EGPA/ Churg-Strauss)

A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)

Vasculitis frequently affects the skin and causes different kinds of rashes (lesions). Because no research studies have provided answers to the question of what therapy for skin vasculitis is best, treatment decisions for patients with skin vasculitis are made based upon the treating doctor’s experience and expert opinions. The doctors involved in this study are hopeful that the information gathered from this study will help doctors and patients understand what the best treatment options are for patients with skin vasculitis.
This study will compare the effectiveness of the three different drugs for the treatment of skin vasculitis, look at how patients respond to the study drugs, and see if there are characteristics that predict which patients will respond to which drugs.

Study Duration: 12 to 18 months

Disease(s): Central Nervous System Vasculitis (CNSV)

Efficacy and Safety of Study Drug NS-229 in Treatment of Eosinophilic Granulomatosis with Polyangiitis

The main purpose of this study is to learn how well the investigational drug NS-229 works and how safe NS-229 is compared with placebo.  An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA) to treat EGPA.

Study Duration: Approximately 9 months